References
- 1. Kamiński K., Obniska J.: Synthesis and anticonvulsant properties of new 1-(2-pyridinyl)- 3-substituted pyrrolidine-2,5-dione derivatives. Acta Pol. Pharm., 65, 457, 2008.
- 2. Lange J. et al.: Synthesis and properties of new cyclic derivatives of succinic acid with anticonvulsant activity. Pharmazie, 32, 82, 1977.
- 3. Litchfield J.T., Wilcoxon F.: A simplified method of evaluating doseeffect experiments. J. Pharmacol. Exp. Ther., 96, 99, 1949.
- 4. Löscher W., Fassbender C.P., Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 8, 79, 1991.
- 5. Łuszczki J.J. et al.: Effects of three N-(carboxyanilinomethyl) derivatives of p-isopropoxyphenylsuccinimide on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol., 648, 74, 2010.
- 6. Łuszczki J.J. et a l.: Inf luence of N-(p-acetylphenyl)-pisopropoxyphenylsuccinimide on the protective action of classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Curr. Issues Pharm. Med. Sci., 26, 76, 2013.
- 7. Łuszczki J.J. et a l.: Inf luence of N-hydroxymethyl-pisopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Epilepsy Res., 100, 27, 2012.
- 8. Łuszczki J.J. et al.: No effect of 3-(N-p-isopropoxyphenylsuccinimid omethylamino)-cinnamic acid on anticonvulsant action of different classical antiepileptic drugs in mouse maximal electroshock-induced seizure model. J. Pre-Clin. Clin. Res., 6, 20, 2012.
- 9. Łuszczki J.J., Kocharov S.L., Czuczwar S.J.: Effect of p-isopropoxyphenylsuccinimide monohydrate on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Pharmacol. Rep., 62, 194, 2010.
- 10. Łuszczki J.J., Kocharov S.L., Czuczwar S.J.: N-(anilinomethyl)-pisopropoxyphenyl- succinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshockinduced seizure model. Neurosci. Res., 64, 267, 2009.
- 11. Rogawski M.A., Bazil C.W.: New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr. Neurol. Neurosci. Rep., 8, 345, 2008.
- 12. Stables J.P., Kupferberg H.J. (1997). The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. In: Molecular and cellular targets for anti-epileptic drugs. Avanzini G., Regesta G., Tanganelli P., Avoli M. (editors). London: John Libbey; p. 191.
- 13. White H.S. et al. (2002). Discovery and preclinical development of antiepileptic drugs. In: Antiepileptic drugs. 5th ed. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E. (editors). Philadelphia: Lippincott Williams & Wilkins; p. 36.
- 14. Zejc A. et al.: Synthesis and anticonvulsant properties of some arylsuccinate methylpyridylimides. Pol. J. Pharmacol. Pharm., 42, 69, 1990.
- 15. Żółkowska D. et al.: Effects of N-(morpholinomethyl)-p-isopropoxyphenylsuccinimide on the protective action of different classical antiepileptic drugs against maximal electroshock-induced tonic seizures in mice. Pharmacol. Rep., 65, 389, 2013.